INTRODUCTION
Hepatoportal sclerosis (HPS) is a rare disease with unknown etiology. Historically, Banti (1) described this disease as morbus Banti in 1910. In 1965, Mikkelsen et al. (2) described 36 patients with splenomegaly and noncirrhotic portal hypertension and called this entity hepatoportal sclerosis. HPS is defined as sclerosis of portal areas in the absence of cirrhosis with patent portal and hepatic veins (2) . There are various synonyms used to describe HPS like idiopathic portal hypertension, regenerative nodular hyperplasia, benign intrahepatic portal hypertension, non-cirrhotic intrahepatic portal hypertension, non-cirrhotic portal hypertension with portal fibrosis and incomplete septal cirrhosis (3) . Mostly, case series were reported from India and Japan (4) (5) (6) . There are also very well documented case series from the West (7). Finally, Schouten et al. (8) have published an extensive review and diagnostic criteria for idiopathic noncirrhotic portal hypertension (INCPH) in 2011.
In this study we aimed to describe the presenting symptoms, clinical and laboratory findings and interesting associations of patients with findings of HPS in their liver biopsies. Some associations we are describing here were not described before in patients with HPS. We also wanted to find out, if hepatoportal sclerosis as a pathological diagnosis represented a uniform clinical presentation and outcome in pediatric population. All, but one, patients in this cohort had their liver biopsies done in our tertiary care institution due to various indications.
MATERIALS AND METHODS
This is a retrospective analysis of patients diagnosed with HPS between 2005 and 2011. Patients, who underwent liver biopsy due to various etiologies in our tertiary care centre and consequently reported as having findings consistent with hepatoportal sclerosis or portal venopathy by the Department of Pathology, were included. Seventeen patients' charts have been reviewed. One patient with Abernethy malformation in CT Angiography and additional 3 patients, who had either partial or complete portal vein thrombosis, were excluded from the study. One additional patient has been excluded from the study because of the missing data.
Patient demographics, clinical presentations, laboratory findings, imaging studies and outcome were noted from the clinic charts. Liver biopsies were done for all but one patient at the same institution with Menghini technique. All specimens were fixed in Bouin's solution and embedded in paraffin. Liver biopsy specimens then were stained with hematoxylin-eosin, Masson's trichrome and immunohistochemical CD34 stain, demonstrating periportal sinusoidal endothelization. Pathology specimens were reviewed by single experienced pediatric pa- thologist. All pathology specimens were examined to rule out cirrhosis, congenital hepatic fibrosis and hepatitis of viral, autoimmune and toxic origin.
Ethics statement
Ethics approval for this retrospective chart review analysis was exempted of review by institutional review board according to the law published in 2011 by the Turkish Ministry of Health. Consent from parents was not obtained due to same regulation. However, no additional blood tests or any analysis were done to collect data for this study.
RESULTS
Twelve patients were enrolled in this study (n = 12, 6 boys, 6 girls). Patient demographics and laboratory findings are shown in Table 1 and 2. Median age at presentation was 10.7 yr (range 6 months-17.7 yr). Mean follow up time was 39 months (range 21-96 months). Two patients had weight percentile below the 3rd percentile (1 boy, 1 girl) at presentation. Five patients had incidentally discovered elevated liver enzymes at presentation. One patient had been referred from another tertiary care centre for liver transplantation after being followed for hepatopulmonary syndrome. Two patients had jaundice and elevated liver enzymes and one patient had pruritus at presentation. Another patient was referred from the Endocrinology Department when she was found to have elevated liver enzymes, where she was followed with the diagnosis of Turner syndrome. Nine patients had elevated ALT levels at onset. Median ALT for all patients was 92 IU/L (range 13-236 IU/L). Six patients had elevated AST levels. Median AST level for all patients was 62 IU/L (range 24-254 IU/L). Only one patient had elevated total bilirubin level (2.39 mg/dL). Mean bilirubin level was 0.82 mg/dL (range 0.14-2.39 mg/dL). Four patients had prolonged International Normalized Ratio with mean INR 1.16 (range 1-1.5). Five patients had thrombocytopenia (range 59,000-439,000/μL). Four of five patients had splenomegaly. All four patients also had low leukocyte count, which suggested hypersplenism. Mean leukocyte count was 7,600/μL (range 2,790-14,600/μL). Hemoglobin levels for age were low in all but 3 patients (median 11.85 g/dL, range 6.3-14 g/dL). One patient with significantly low albumin had been diagnosed with celiac disease. Three patients had low albumin levels (albumin < 3.5 g/dL). Mean albumin level for all patients was 3.75 g/dL (range 2.48-4.35 g/dL). Four patients had smooth muscle antibody (SMA) positivity. One of them had positive SMA in 1:320 titer, whereas the other was positive in 1:20 titer. Two patients had only qualitatively positive results. None of these patients had hypergammaglobulinemia and/or findings consistent with autoimmune liver disease in their liver biopsy specimens. One patient had positive anti-cardiolipin (ACL) IgG and IgM antibodies (40 and 46 phospholipid units respectively; < 22.9 units is negative). One patient had inciden- (13) have reported hepatopulmonary syndrome in 2 patients with idiopathic portal hypertension. In their cohort there were 19 patients diagnosed with idiopathic portal hypertension and the prevalence was found 10.5%, which is similar to our results. However it is not mentioned in the article, whether these two patients have been transplanted or not. Isabel Fiel et al. (14) have reported a case series, consisting of 8 adult patients with HPS requiring liver transplantation. None of them was cirrhotic and 2 of them had portal vein thrombosis. Seven patients in this cohort had variceal bleeding as presenting symptom. When compared with our data, we had 3 patients with esophageal varices and none had variceal bleeding. Two patients in our cohort were treated with consecutive endoscopic variceal band ligation treatment without complications. All 3 patients with varices were on propranolol treatment. Krasinkas et al. (15) have reported 16 cases with noncirrhotic portal hypertension who underwent orthotopic liver transplantation. All were adult patients and none had hepatopulmonary syndrome. However, in this case series, 13 patients had clinical cirrhosis. Eleven of 13 patients had radiological evidence of cirrhosis and 4 had biopsy proven cirrhosis. Additional 3 cases who underwent liver transplantation have been reported by Geramizadeh et al. (16) 
in 2008.
Besides serious liver disease and associated complications, HPS has been reported in association with other diseases. Girard et al. (17) reported a child with Adams-Oliver syndrome and HPS. They have hypothesized that a vascular anomaly and thrombosis may be the etiology for this condition based on the fact that the patient had portal vein thrombosis and Factor V Leiden mutation. One year later, Pouessel et al. (18) have reported an additional child with Adams-Oliver syndrome. In our case series, none of the patients had Adams-Oliver syndrome, but we report an 11 yr old girl with Turner syndrome (TS). This patient had been referred by the Endocrinology Department in our institution, where she was found to have elevated liver enzymes incidentally, during a routine blood work. On physical examination, she did not have hepatosplenomegaly, or clinical findings consistent with portal hypertension, and remaining laboratory findings were normal. In the literature, liver disease in TS patients is reported to be common. Roulot et al. (19) have reported on vascular involvement of the liver in TS. They have included 27 TS patients with liver disease from 6 centers. They reported 10 patients with architectural changes in liver biopsy. Six patients had nodular regenerative hyperplasia (NRH), 2 had multiple focal nodular hyperplasia and 2 had cirrhosis. Among the patients with architectural changes, 4 had portal hypertension. Vascular lesions were shown in 2 patients with NRH, which was obliterative portal venopathy. Interestingly, they reported two patients with positive SMA, without hypergamaglobulinemia and autoimmune liver disease. In our cohort we had 4 patients with positive SMA. One of the problems with SMA autoantibody positivity in our cohort was that, 2 patients had only qualitative analysis and another had low titer positive results. None of the patients had hypergammaglobulinemia and/or autoimmune liver disease positivity in liver biopsy. However, in a study group of 12 children, positive SMA in 4 patients is probably not coincidental (33%). In a recent study from Brazil, seven hundred twenty-five healthy subjects were investigated for non-organ-specific autoantibodies. Approximately 10% of their cohort had positive SMA in 1:40 titer (20) . In another study from Malaysia, 101 serum samples of 69 Malay, 18 Indian and 14 Chinese adults were studied for different autoantibodies including anti-nuclear, anti-mitochondrial, anti-smooth muscle and anti-parietal cell antibodies and none of 101 subjects had positive SMA (21). It is possible, different populations with different ethnic backgrounds have different autoantibody prevalence profiles in healthy populations. Unfortunately there is no published data available regarding the prevalence of SMA positivity in healthy Turkish population, which would help us making a comparison with our specific cohort. Although, it is not possible to make a conclusion with such small http://dx.doi.org/10.3346/jkms.2013.28.10.1507 numbers in our study, there might be an autoimmune process in etiology, affecting portal areas, causing ultimately sclerosis. In the presence of well described association of CD with HPS, the hypothesis of autoimmunity in the etiology of HPS becomes stronger, as CD is a known autoimmune condition.
Celiac disease (CD) and hepatoportal sclerosis has been reported previously in 2 adult cases. M'saddek (22) reported a 31 yr old patient with CD and splenomegaly. This patient did not have any abnormal liver function tests. Zamani et al. (23) have reported a 54-yr-old man with portal hypertension and CD, where his symptoms improved on a gluten-free diet. In pediatric age group, there are no published articles mentioning this association to the best of our knowledge. In our case series, one patient had been diagnosed incidentally with CD, where we were performing an upper GI endoscopy to check varices. His anti-gliadin antibodies and tissue transglutaminase antibodies found dramatically high afterwards. Another patient had positive antigliadin antibodies positive, without any CD findings in small bowel mucosa. These two children in our study group may be the first reported HPS patients; one with manifest CD, and the other with only positive serology, but the disease.
HPS has been described in some patients with HIV infection. Schiano et al. (24) have reported HPS in 2007 in 4 HIV (+) adults. They postulated that HPS might be due to intrahepatic microthrombosis or an altered hepatic fibrogenesis related to highly active antiretroviral therapy or due to HIV itself. Vispo et al. (25) have reported 12 HIV infected adult patients with HPS. All patients had been treated with a purine analogue, didanosine, for long time. Liver biopsies were available in 11 patients. None of the biopsies showed cirrhosis. Pathological diagnosis was HPS in 8 patients. They have postulated that, didanosine may have contributed to portal vein or its branches obliteration. In our cohort, none of the patients was tested for HIV infection. This was due to lack of risk factors, clinical and laboratory findings, which would raise the suspicion of HIV infection.
There are a lot of synonyms used for hepatoportal sclerosis. Schouten et al. (8) have used the term INCPH in their review in 2011. We have preferred to use hepatoportal sclerosis and not INCPH just because our patients did not fulfill all the criteria required to make the diagnosis of INCPH (Table 3 ). There were children in our study group with hepatoportal sclerosis, who did not show symptoms of portal hypertension, but had associations described with INCPH and/or hepatoportal sclerosis. It was possible that, children did not develop portal hypertension findings at early stages and we have diagnosed these patients before portal hypertension findings have developed. We can speculate that children without portal hypertension might develop portal hypertension at some stage during their follow-up. Regarding the diagnostic criteria, some exceptions or modifications may be required for the diagnosis of INCPH especially in pediatric age group.
In summary, we wanted to investigate retrospectively, whether pediatric patients, underwent liver biopsy and been diagnosed with hepatoportal sclerosis, had a uniform presentation, including portal hypertension findings. We found out that, there was no uniformity among these patients. Patients in our cohort did not necessarily have findings of portal hypertension.
There are some weaknesses in this article. First of all, data had been collected retrospectively. There were some patients, where we could not collect all the data we aimed. Another weakness is, there might be some patients with HPS we are missing. Although they have HPS, these patients may not have been registered in the pathology database under the diagnosis of HPS, which may cause eventually issues with the power of the study. However, power is a chronic problem of pediatric cohorts in rare conditions, where it is extremely difficult to collect enough num bers of patients, unless multicentre studies or registries are plann ed ahead.
In conclusion, for pediatric age group with hepatoportal sclerosis findings in liver biopsy, who have not fulfilled the criteria for INCPH yet, it may be necessary to consider HPS as the initial diagnosis and once portal hypertension develops, IN-CPH diagnosis can be made. We need multi-center studies and registries to understand the characteristics of HPS in children in detail. 
